RIGL vs WELL · P/E 9.1, rev $179.3M vs P/E 100, rev $10.84B
Rigel Pharmaceuticals Inc (RIGL) versus Welltower Inc (WELL) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Welltower Inc (WELL) is a reit - healthcare facilities company listed on NYSE.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported WELL revenue for 2025-12-31 was $10.84B. Net income was $936.8M. Revenue was up 35.6% from 2024-12-31 to 2025-12-31. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
Not investment advice. Open the RIGL and WELL stock pages for the full models.
Not investment advice.